Today, Teva is announcing the proposed leadership team for its post-close Global Generics Business Development and Portfolio Management organization. This team will report into Dan Motto who is expected to become SVP, Global Business Development and Portfolio Management upon the anticipated close of the transaction. I have attached Teva’s full announcement for your review and also highlighted Allergan team member appointments below.
Nathalie Leitch, currently VP, Portfolio Management, Americas, has been appointed to serve as Teva’s SVP, Portfolio North America. She will be responsible for establishing and leading the product and portfolio strategies for the US and Canada.